223 related articles for article (PubMed ID: 24206926)
1. A fully caninised anti-NGF monoclonal antibody for pain relief in dogs.
Gearing DP; Virtue ER; Gearing RP; Drew AC
BMC Vet Res; 2013 Nov; 9():226. PubMed ID: 24206926
[TBL] [Abstract][Full Text] [Related]
2. In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats.
Gearing DP; Huebner M; Virtue ER; Knight K; Hansen P; Lascelles BD; Gearing RP; Drew AC
J Vet Intern Med; 2016 Jul; 30(4):1129-37. PubMed ID: 27306920
[TBL] [Abstract][Full Text] [Related]
3. Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats.
Enomoto M; Mantyh PW; Murrell J; Innes JF; Lascelles BDX
Vet Rec; 2019 Jan; 184(1):23. PubMed ID: 30368458
[TBL] [Abstract][Full Text] [Related]
4. A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain.
Lascelles BD; Knazovicky D; Case B; Freire M; Innes JF; Drew AC; Gearing DP
BMC Vet Res; 2015 Apr; 11():101. PubMed ID: 25926287
[TBL] [Abstract][Full Text] [Related]
5. Canine Brief Pain Inventory scores for dogs with osteoarthritis before and after administration of a monoclonal antibody against nerve growth factor.
Webster RP; Anderson GI; Gearing DP
Am J Vet Res; 2014 Jun; 75(6):532-5. PubMed ID: 24866508
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of a high-affinity monoclonal antibody against nerve growth factor.
Liu S; Shen Y; Chen P; Guo C; Zhang G; Jiang X; He J; Yang J
Protein Expr Purif; 2022 Jan; 189():105966. PubMed ID: 34627999
[TBL] [Abstract][Full Text] [Related]
7. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
Bannwarth B; Kostine M
Drugs; 2017 Sep; 77(13):1377-1387. PubMed ID: 28660479
[TBL] [Abstract][Full Text] [Related]
8. Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis.
von Loga IS; El-Turabi A; Jostins L; Miotla-Zarebska J; Mackay-Alderson J; Zeltins A; Parisi I; Bachmann MF; Vincent TL
Ann Rheum Dis; 2019 May; 78(5):672-675. PubMed ID: 30862648
[TBL] [Abstract][Full Text] [Related]
9. Characterization of ultra-high affinity monoclonal antibodies with a dimeric, symmetrical antigen: inhibition of the receptor recognition site of nerve growth factor.
Vroegop SM; Crumm E; Buxser SE
Mol Immunol; 1992 Mar; 29(3):411-23. PubMed ID: 1313539
[TBL] [Abstract][Full Text] [Related]
10. Pro region engineering of nerve growth factor by deep mutational scanning enables a yeast platform for conformational epitope mapping of anti-NGF monoclonal antibodies.
Medina-Cucurella AV; Zhu Y; Bowen SJ; Bergeron LM; Whitehead TA
Biotechnol Bioeng; 2018 Aug; 115(8):1925-1937. PubMed ID: 29663315
[TBL] [Abstract][Full Text] [Related]
11. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain.
Cattaneo A
Curr Opin Mol Ther; 2010 Feb; 12(1):94-106. PubMed ID: 20140821
[TBL] [Abstract][Full Text] [Related]
12. Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.
Krautmann M; Walters R; Cole P; Tena J; Bergeron LM; Messamore J; Mwangi D; Rai S; Dominowski P; Saad K; Zhu Y; Guillot M; Chouinard L
Vet J; 2021 Oct; 276():105733. PubMed ID: 34391918
[TBL] [Abstract][Full Text] [Related]
13. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?
Bannwarth B; Kostine M
Drugs; 2014 Apr; 74(6):619-26. PubMed ID: 24691709
[TBL] [Abstract][Full Text] [Related]
14. Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody.
Covaceuszach S; Marinelli S; Krastanova I; Ugolini G; Pavone F; Lamba D; Cattaneo A
PLoS One; 2012; 7(3):e32212. PubMed ID: 22403636
[TBL] [Abstract][Full Text] [Related]
15. A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease-Associated Pain: A Pilot Proof of Concept Study.
Gruen ME; Thomson AE; Griffith EH; Paradise H; Gearing DP; Lascelles BD
J Vet Intern Med; 2016 Jul; 30(4):1138-48. PubMed ID: 27334504
[TBL] [Abstract][Full Text] [Related]
16. Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement.
Rosales C; Jeglum KA; Obrocka M; Steplewski Z
Cell Immunol; 1988 Sep; 115(2):420-8. PubMed ID: 3409330
[TBL] [Abstract][Full Text] [Related]
17. Effect of administration of antibodies against nerve growth factor in a rat model of muscle injury.
Suzuki M; Inage K; Sakuma Y; Orita S; Yamauchi K; Suzuki T; Suzuki M; Kubota G; Oikawa Y; Sainoh T; Sato J; Fujimoto K; Shiga Y; Abe K; Kanamoto H; Takahashi K; Ohtori S
Injury; 2016 Mar; 47(3):609-12. PubMed ID: 26653267
[TBL] [Abstract][Full Text] [Related]
18. Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.
Farrell M; Adams R; von Pfeil DJF
Vet J; 2024 Jun; 305():106104. PubMed ID: 38580157
[TBL] [Abstract][Full Text] [Related]
19. Targeting nerve growth factor in pain: what is the therapeutic potential?
Watson JJ; Allen SJ; Dawbarn D
BioDrugs; 2008; 22(6):349-59. PubMed ID: 18998753
[TBL] [Abstract][Full Text] [Related]
20. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma.
Rue SM; Eckelman BP; Efe JA; Bloink K; Deveraux QL; Lowery D; Nasoff M
Vet Immunol Immunopathol; 2015 Apr; 164(3-4):148-59. PubMed ID: 25764941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
